These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 6383330)

  • 21. In vitro and in vivo antitumor activity of ZENECA ZD0490, a recombinant ricin A-chain immunotoxin for the treatment of colorectal cancer.
    Calvete JA; Newell DR; Wright AF; Rose MS
    Cancer Res; 1994 Sep; 54(17):4684-90. PubMed ID: 8062265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
    Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
    Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen.
    Raso V; Ritz J; Basala M; Schlossman SF
    Cancer Res; 1982 Feb; 42(2):457-64. PubMed ID: 6948605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Use of monoclonal antibodies in the immunotherapy of neoplasms].
    Robak T
    Przegl Lek; 1989; 46(4):420-6. PubMed ID: 2672121
    [No Abstract]   [Full Text] [Related]  

  • 25. Monoclonal anti-MM46 antibody:ricin A chain conjugate: in vitro and in vivo antitumor activity.
    Seto M; Umemoto N; Saito M; Masuho Y; Hara T; Takahashi T
    Cancer Res; 1982 Dec; 42(12):5209-15. PubMed ID: 6814753
    [No Abstract]   [Full Text] [Related]  

  • 26. Immunotoxins containing ricin or its A chain.
    Vitetta ES; Thorpe PE
    Semin Cell Biol; 1991 Feb; 2(1):47-58. PubMed ID: 1954343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted cytotoxic effect of anti-JL1 immunotoxin against a human leukemic cell line and its clinical implications.
    Shin YK; Choi YL; Choi EY; Kim MK; Kook MC; Chung J; Choi YK; Kim HS; Song HG; Park SH
    Cancer Immunol Immunother; 2003 Aug; 52(8):506-12. PubMed ID: 12768327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antitumor immunotherapy].
    Błoński JZ; Warzocha K
    Postepy Hig Med Dosw; 1994; 48(6):701-28. PubMed ID: 7675731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
    Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
    Clin Cancer Res; 2000 Sep; 6(9):3621-8. PubMed ID: 10999754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specific inhibition of in vitro lymphocyte transformation by an anti-pan T cell (gp67) ricin A chain immunotoxin.
    Kernan NA; Knowles RW; Burns MJ; Broxmeyer HE; Lu L; Lee HM; Kawahata RT; Scannon PJ; Dupont B
    J Immunol; 1984 Jul; 133(1):137-46. PubMed ID: 6609971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity.
    Kaliberov SA; Chiz S; Kaliberova LN; Krendelchtchikova V; Della Manna D; Zhou T; Buchsbaum DJ
    Cancer Gene Ther; 2006 Feb; 13(2):203-14. PubMed ID: 16082379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinetics of cytotoxicity induced by immunotoxins. Enhancement by lysosomotropic amines and carboxylic ionophores.
    Casellas P; Bourrie BJ; Gros P; Jansen FK
    J Biol Chem; 1984 Aug; 259(15):9359-64. PubMed ID: 6746651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Targeting of antitumor drugs with monoclonal antibodies].
    Monneret C; Florent JC
    Bull Cancer; 2000 Nov; 87(11):829-38. PubMed ID: 11125291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antidisialoganglioside ricin A-chain immunotoxins show potent antitumor effects in vitro and in a disseminated human neuroblastoma severe combined immunodeficiency mouse model.
    Gottstein C; Schön G; Tawadros S; Kube D; Wargalla-Plate UC; Hansmann ML; Wacker HH; Berthold F; Diehl V; Engert A
    Cancer Res; 1994 Dec; 54(23):6186-93. PubMed ID: 7954465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale for immunotoxin therapy of metastatic prostate carcinoma formatted as a multi-stage delivery system.
    Webb KS; Poulton SH; Liberman SN; Walther PJ
    J Urol; 1989 Aug; 142(2 Pt 1):425-32. PubMed ID: 2787412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.
    Grossbard ML; Multani PS; Freedman AS; O'Day S; Gribben JG; Rhuda C; Neuberg D; Nadler LM
    Clin Cancer Res; 1999 Sep; 5(9):2392-8. PubMed ID: 10499609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
    Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
    Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma.
    Multani PS; O'Day S; Nadler LM; Grossbard ML
    Clin Cancer Res; 1998 Nov; 4(11):2599-604. PubMed ID: 9829722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Advances in research on monoclonal antibody agents for cancer therapy].
    Zhen Y
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Feb; 22(1):9-13. PubMed ID: 12903485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.